

Application Serial No. 10/663,875

RECEIVED
CENTRAL FAX CENTERPATENT
89188.0050

JAN 22 2007

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently amended) An isolated RNA comprising an intron RNA that is released in a cell, thereby modulating the function of a target gene, ~~wherein the isolated RNA does not contain a combination of a splice donor site that includes 5' GU(A/G)AGU 3' and a splice acceptor site that includes 5' CU(A/G)A(C/U)NG 3'.~~
2. (Currently amended) The isolated RNA of claim 1, wherein the isolated RNA contains a splice donor site that includes 5'-GUA(A/-)GAG(G/U)-3', a splice acceptor site that includes 5'-G(A/U/-)(U/G)(C/G)C(U/C)(G/A)CAG-3' (SEQ ID NO: 1), a branch site that includes 5'-UACU(A/U)A(C/U)(-/C)-3', a polypyrimidine tract that includes 5'-(U(C/U))₁₋₃(C/-)U₇₋₁₂C(C/-)-3' (SEQ ID NO: 2) ~~or 5'-(UC)₇₋₁₂NCUAG(G/-)-3' (SEQ ID NO: 3),~~ or a combination thereof.
3. (Original) The isolated RNA of claim 2, wherein the cell is a mammalian cell.
4. (Currently amended) The isolated RNA of claim 2, wherein the splice donor site is ~~5'-AGGUAAGAGGAU 3' (SEQ ID NO: 4), 5'-AGGUAAGAGU 3' (SEQ ID NO: 5), 5'-AGGUAGAGU 3', or contains 5'-AGGUAAGU-3'.~~
5. (Currently amended) The isolated RNA of claim 2, wherein the splice acceptor site is ~~5'-GAUAUCCUGCAGG 3' (SEQ ID NO: 6), 5'-GGCUGCAGG 3', or contains 5'-CCACAGC-3'.~~
6. (Currently amended) The isolated RNA of claim 2, wherein the branch site is ~~contains 5'-UACUAAC-3' or 5'-UACUUAUC 3'.~~
7. (Currently amended) An isolated RNA comprising an intron RNA that is released in a mammalian cell, thereby modulating the function of a target gene, ~~wherein the isolated RNA does not contain a combination of a splice donor site that includes 5' GU(A/G)AGU 3' and a splice acceptor site that includes 5' CU(A/G)A(C/U)NG 3'.~~

Application Serial No. 10/663,875

PATENT
89188.0050

8. (Currently amended) An isolated RNA comprising an intron RNA that is released in a mammalian cell, thereby modulating the function of a target gene, wherein the isolated RNA contains a splice donor site that includes 5'-GUA(A/-)GAG(G/U)-3', a splice acceptor site that includes 5'-G(A/U/-)(U/G)(C/G)C(U/C)(G/A)CAG-3' (SEQ ID NO: 1), a branch site that includes 5'-UACU(A/U)A(C/U)(-/C)-3', a poly-pyrimidine tract that includes 5'-(U(C/U))₁₋₃(C/-)U₇₋₁₂C(C/-)-3' (SEQ ID NO: 2) or 5'-(UC)₇₋₁₂NCUAG(G/-)-3' (SEQ ID NO: 3), or a combination thereof.
9. (Withdrawn) A DNA template for the isolated RNA of claim 1.
10. (Withdrawn) An expression vector comprising the DNA of claim 9.
11. (Original) A cultivated cell comprising the isolated RNA of claim 1.
12. (Withdrawn) A cultivated cell comprising the DNA of claim 9.
13. (Withdrawn) An animal comprising the isolated RNA of claim 1.
14. (Withdrawn) The animal of claim 13, wherein the animal is a mammal.
15. (Withdrawn) The animal of claim 14, wherein the animal is a mouse.
16. (Withdrawn) An animal comprising the DNA of claim 9.
17. (Withdrawn) The animal of claim 16, wherein the animal is a mammal.
18. (Withdrawn) The animal of claim 17, wherein the animal is a mouse.
19. (Original) A composition comprising the isolated RNA of claim 1.
20. (Withdrawn) A composition comprising the DNA of claim 9.
21. (Withdrawn) A method of producing an intron RNA, comprising cultivating the cell of claim 11 to allow release of the intron RNA.
22. (Withdrawn) A method of producing an intron RNA, comprising cultivating the cell of claim 12 to allow expression and release of the intron RNA.
23. (Withdrawn) A method of modulating the function of a target gene in a cell, comprising introducing into a cell an effective amount of the isolated RNA of claim 1, wherein the intron RNA is released in the cell, thereby modulating the function of a target gene.

Application Serial No. 10/663,875

PATENT
89188.0050

24. (Withdrawn) A method of modulating the function of a target gene in a cell, comprising introducing into a cell an effective amount of the DNA of claim 9, wherein the intron RNA is expressed and released in the cell, thereby modulating the function of a target gene.
25. (Withdrawn) A composition comprising a chemokine and an isolated RNA, wherein the isolated RNA has an intron RNA that is released in a cell, thereby modulating the function of a target gene, and the isolated RNA does not contain a combination of a splice donor site that includes 5'-GU(A/G)AGU-3' and a splice acceptor site that includes 5'-CU(A/G)A(C/U)NG-3'.
26. (Withdrawn) The composition of claim 25, wherein the cell is a mammalian cell.
27. (Withdrawn) The composition of claim 26, wherein the chemokine is interleukin-2.
28. (Withdrawn) The composition of claim 25, wherein the cell is infected by a virus.
29. (Withdrawn) The composition of claim 28, wherein the cell is infected by HIV-1.
30. (Withdrawn) The composition of claim 29, wherein the chemokine is interleukin-2 and the intron RNA modulates the function of an HIV-1 genomic sequence.
31. (Withdrawn) A method of modulating the function of a target gene in a cell, comprising administering into a cell an effective amount of the composition of claim 25.
32. (Withdrawn) A composition comprising a chemokine and a DNA template for an isolated RNA, wherein the isolated RNA has an intron RNA that is released in a cell, thereby modulating the function of a target gene, and the isolated RNA does not contain a combination of a splice donor site that includes 5'-GU(A/G)AGU-3' and a splice acceptor site that includes 5'-CU(A/G)A(C/U)NG-3'.
33. (Withdrawn) The composition of claim 32, wherein the cell is a mammalian cell.
34. (Withdrawn) The composition of claim 33, wherein the chemokine is interleukin-2.
35. (Withdrawn) The composition of claim 32, wherein the cell is infected by a virus.

Application Serial No. 10/663,875

PATENT
89188.0050

36. (Withdrawn) The composition of claim 35, wherein the cell is infected by HIV-1.
37. (Withdrawn) The composition of claim 36, wherein the chemokine is interleukin-2 and the intron RNA modulates the function of an HIV-1 genomic sequence.
38. (Withdrawn) A method of modulating the function of a target gene in a cell, comprising administering into a cell an effective amount of the composition of claim 32.
39. (Withdrawn) A composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a cell.
40. (Withdrawn) The composition of claim 39, wherein the cell is a mammalian cell.
41. (Withdrawn) The composition of claim 39, wherein the cell is infected by a virus.
42. (Withdrawn) The composition of claim 41, wherein the cell is infected by HIV-1.
43. (Withdrawn) The composition of claim 42, wherein the target genes are selected from the group consisting of HIV-1 genes and cellular genes.
44. (Withdrawn) The composition of claim 43, wherein the cellular genes include Naf1b, Nb2HP, and Tax1BP.
45. (Withdrawn) The composition of claim 44, wherein the one or more agents include one or more DNA-RNA hybrids.
46. (Withdrawn) The composition of claim 44, wherein the one or more agents include one or more exogenous intron RNAs.
47. (Withdrawn) A composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a mammalian cell.
48. (Withdrawn) A composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a cell, wherein the one or more agents include one or more DNA-RNA hybrids.
49. (Withdrawn) A composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a cell, wherein the one or more agents include one or more exogenous intron RNAs.

Application Serial No. 10/663,875

PATENT
89188.0050

50. (Withdrawn) A method of modulating the functions of genes in a cell, comprising administering into a cell an effective amount of the composition of claim 39.
51. (Withdrawn) The method of claim 50, wherein the cell is a mammalian cell.
52. (Withdrawn) The method of claim 50, wherein the cell is infected by a virus.
53. (Withdrawn) The method of claim 52, wherein the cell is infected by HIV-1.
54. (Withdrawn) The method of claim 53, wherein the target genes are selected from the group consisting of HIV-1 genes and cellular genes.
55. (Withdrawn) The method of claim 54, wherein the cellular genes include Naf1b, Nb2HP, and Tax1BP.
56. (Withdrawn) The method of claim 55, wherein the one or more agents include one or more DNA-RNA hybrids.
57. (Withdrawn) The method of claim 55, wherein the one or more agents include one or more exogenous intron RNAs.